|
Chantilly, Va.— October 30, 2019--Perspecta Inc. announced today that its innovative research arm, Perspecta Labs, was awarded a task order from the United States Army as the Applied Research and Experimentation Partner (AREP) for the cybersecurity Collaborative Research Alliance (CRA) program. The program, which represents continuing work for the company, has a maximum potential value of $25 million over a five-year period of performance if all options are exercised. The cybersecurity CRA is a collaborative alliance between the Combat Capabilities Development Command Army Research Laboratory, CCDC C5ISR Center, academia and industry to advance the foundation of cyber science in the context of Army networks. Perspecta Labs has been conducting research as a member of the CRA since 2014. Under the new AREP task order, Perspecta Labs will continue to support the CRA with applied research and experimentation and assist with the accelerated transition of this research into the field. Specifically, the company will leverage and extend its CyberVAN testbed to provide sophisticated capabilities for cyber experimentation in tactical, as well as strategic, environments.
“At Perspecta Labs, we pride ourselves on successfully transitioning the advanced research we conduct and innovative solutions we invent to real-world applications,” said Petros Mouchtaris, Ph.D., president of Perspecta Labs. “We are excited to lead the efforts of transferring cyber technology research into operational capabilities to support Army missions and provide warfighters with resilient, secure, intelligent networks in dynamic and hostile battlefield environments.” Perspecta Labs’ CyberVAN testbed is the primary mechanism for conducting experimentation, validation, maturation and hardening of novel CRA research in preparation for the successful and seamless transition to Army networks. CyberVAN provides a realistic, high-fidelity cyber environment that scales to handle large networks, incorporates wired and wireless networking effects accurately, and provides flexible, easy-to-use libraries and interfaces for users. About Perspecta Inc. At Perspecta (NYSE: PRSP), we question, we seek and we solve. Perspecta brings a diverse set of capabilities to our U.S. government customers in defense, intelligence, civilian, health care and state and local markets. Our 270+ issued, licensed and pending patents are more than just pieces of paper, they tell the story of our innovation. With offerings in mission services, digital transformation and enterprise operations, our team of 14,000 engineers, analysts, investigators and architects work tirelessly to not only execute the mission, but build and support the backbone that enables it. Perspecta was formed to take on big challenges. We are an engine for growth and success and we enable our customers to build a better nation. For more information about Perspecta, visit perspecta.com. # # # This press release may contain forward-looking statements. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Perspecta and are subject to significant risks and uncertainty. Readers are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Perspecta undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Perspecta believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve a variety of risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. Contact Lorraine M. Corcoran Vice President, Corporate Communications 571.313.6054 office 301.529.9429 mobile lorraine.corcoran@perspecta.com M. Stuart Davis Vice President, Investor Relations 703.547.0300 office 571.424.6262 mobile stuart.davis@perspecta.com Comments are closed.
|
Sort by topic
All
Sort by date
February 2023
|
